Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO Complete if Known INFORMATION DISCLOSURE **Application Number** 10/562,202 STATEMENT BY APPLICANT 6/25/2004 **Filing Date First Named Inventor** Osamu HONMO Date Submitted: ________ 1 2010 Art Unit 1633 (use as many sheets as necessary) **Examiner Name** Scott Long Sheet & TRADEMA of Attorney Docket Number 033873-0108

U.S. PATENT DOCUMENTS					
Examin er Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴⁻ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	H1	Supplementary European Search Report completed May 27, 2009, mailed June 5, 2009, in corresponding EP 04 74 6855, 3 pages.	
	H2	CHEN et al., "Human Bone Marrow Stromal Cell Cultures Conditioned by Traumatic Brain Tissue Extracts: Growth Factor Production," Journal of Neuroscience Research, August 2, 2002, 69(5):687-691.	
	Н3	CHEN et al., "Intracerebral transplantation of bone marrow with BDNF after MCAo in rat," Neuropharmacology, March 1, 2000, 39(5):711-716.	
	H4	ERICES et al., "Mesenchymal progenitor cells in human umbilical cord blood," British Journal of Hematology, 2000, 109:235-242.	
	H5	KURIWAKA et al., "Isolation of mesenchymal stem cells in cord blood and placental blood, and induction of differentiation of such mesenchymal stem cells," Nihon Seikie-Geka-Gakkai Zasshie, 2002, 76(8):S1052, 2-D-7, with English translation of excerpt, 2 pages.	
	H6	MAHMOOD et al., "Intracerebral Transplantation of Marrow Stromal Cells Cultured with Neurotrophic Factors Promotes Functional Recovery in Adult Rats Subjected to Traumatic Brain Injury," Journal of Neurotrauma, December 1, 2002, 19(12):1609-1617.	
	H7	SANCHEZ-RAMOS et al,. "Adult Bone Marrow Stromal Cells Differentiate into Neural Cells <i>in Vitro</i> ," Experimental Neurology, January 1, 2000, 164:247-256.	
	H8	TERASHIMA et al., "Cell separation technology and application by a novel filter system," Cell, 2001, 33(11):436-439, with partial English translation, 1 page.	

Examiner Signature	/Scott Long/ (07/28/2010)	Date Considered	07/28/2010

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.